Predictive Biomarkers for the Efficacy of PARP Inhibitors in Ovarian Cancer: an Updated Systematic Review

Overview

Journal BJC Rep

Publisher Nature Portfolio

Date 2025 Mar 12

PMID 40069561

Authors

Ying-Wen Wang

Isaac Allen

Gabriel Funingana

Marc Tischkowitz

Yvonne Walburga Joko-Fru

Affiliations

Soon will be listed here.

Abstract

Background: PARP inhibitors are effective in treating ovarian cancer, especially for BRCA1/2 pathogenic variant carriers and those with HRD (homologous recombination deficiency). Concerns over toxicity and costs have led to the search for predictive biomarkers. We present an updated systematic review, expanding on a previous ESMO review on PARP inhibitor biomarkers.

Methods: Following ESMO's 2020 review protocol, we extended our search to March 31, 2023, including PubMed and clinical trial data. We also reviewed the reference lists of review articles. We conducted a meta-analysis using a random-effects model to evaluate hazard ratios and assess the predictive potential of biomarkers and the effectiveness of PARP inhibitors in survival.

Results: We found 375 articles, 103 of which were included after screening (62 primary research, 41 reviews). HRD remained the primary biomarker (95%), particularly BRCA1/2 variants (77%). In the non-HRD category, six articles (10%) introduced innovative biomarkers, including ADP-ribosylation, HOXA9 promoter methylation, patient-derived organoids, KELIM, and SLFN11.

Discussion: Prospective assessment of real-time homologous recombination repair via nuclear RAD51 levels shows promise but needs validation. Emerging biomarkers like ADP-ribosylation, HOXA9 promoter methylation, patient-derived organoids, KELIM, and SLFN11 offer potential but require large-scale validation.

References

Rusan M, Andersen R, Jakobsen A, Steffensen K . Circulating HOXA9-methylated tumour DNA: A novel biomarker of response to poly (ADP-ribose) polymerase inhibition in BRCA-mutated epithelial ovarian cancer. Eur J Cancer. 2019; 125:121-129. DOI: 10.1016/j.ejca.2019.11.012. View

Kurian A, Ward K, Abrahamse P, Bondarenko I, Hamilton A, Deapen D . Time Trends in Receipt of Germline Genetic Testing and Results for Women Diagnosed With Breast Cancer or Ovarian Cancer, 2012-2019. J Clin Oncol. 2021; 39(15):1631-1640. PMC: 8274804. DOI: 10.1200/JCO.20.02785. View

Ray-Coquard I, Leary A, Pignata S, Cropet C, Gonzalez-Martin A, Marth C . Olaparib plus bevacizumab first-line maintenance in ovarian cancer: final overall survival results from the PAOLA-1/ENGOT-ov25 trial. Ann Oncol. 2023; 34(8):681-692. DOI: 10.1016/j.annonc.2023.05.005. View

Alsop K, Fereday S, Meldrum C, DeFazio A, Emmanuel C, George J . BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group. J Clin Oncol. 2012; 30(21):2654-63. PMC: 3413277. DOI: 10.1200/JCO.2011.39.8545. View

Frampton G, Fichtenholtz A, Otto G, Wang K, Downing S, He J . Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing. Nat Biotechnol. 2013; 31(11):1023-31. PMC: 5710001. DOI: 10.1038/nbt.2696. View

Pujade-Lauraine E, Brown J, Barnicle A, Wessen J, Lao-Sirieix P, Criscione S . Homologous Recombination Repair Gene Mutations to Predict Olaparib Plus Bevacizumab Efficacy in the First-Line Ovarian Cancer PAOLA-1/ENGOT-ov25 Trial. JCO Precis Oncol. 2023; 7:e2200258. PMC: 9928987. DOI: 10.1200/PO.22.00258. View

Ledermann J, Oza A, Lorusso D, Aghajanian C, Oaknin A, Dean A . Rucaparib for patients with platinum-sensitive, recurrent ovarian carcinoma (ARIEL3): post-progression outcomes and updated safety results from a randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 2020; 21(5):710-722. PMC: 8210534. DOI: 10.1016/S1470-2045(20)30061-9. View

Mao Z, Bozzella M, Seluanov A, Gorbunova V . DNA repair by nonhomologous end joining and homologous recombination during cell cycle in human cells. Cell Cycle. 2008; 7(18):2902-6. PMC: 2754209. DOI: 10.4161/cc.7.18.6679. View

Cruz C, Castroviejo-Bermejo M, Gutierrez-Enriquez S, Llop-Guevara A, Ibrahim Y, Gris-Oliver A . RAD51 foci as a functional biomarker of homologous recombination repair and PARP inhibitor resistance in germline BRCA-mutated breast cancer. Ann Oncol. 2018; 29(5):1203-1210. PMC: 5961353. DOI: 10.1093/annonc/mdy099. View

10.

Clamp A, Lorusso D, Oza A, Aghajanian C, Oaknin A, Dean A . Rucaparib maintenance treatment for recurrent ovarian carcinoma: the effects of progression-free interval and prior therapies on efficacy and safety in the randomized phase III trial ARIEL3. Int J Gynecol Cancer. 2021; 31(7):949-958. PMC: 9445915. DOI: 10.1136/ijgc-2020-002240. View

11.

Eccles D, Mitchell G, Monteiro A, Schmutzler R, Couch F, Spurdle A . BRCA1 and BRCA2 genetic testing-pitfalls and recommendations for managing variants of uncertain clinical significance. Ann Oncol. 2015; 26(10):2057-65. PMC: 5006185. DOI: 10.1093/annonc/mdv278. View

12.

Del Campo J, Matulonis U, Malander S, Provencher D, Mahner S, Follana P . Niraparib Maintenance Therapy in Patients With Recurrent Ovarian Cancer After a Partial Response to the Last Platinum-Based Chemotherapy in the ENGOT-OV16/NOVA Trial. J Clin Oncol. 2019; 37(32):2968-2973. PMC: 6839909. DOI: 10.1200/JCO.18.02238. View

13.

ODonnell R, Kaufmann A, Woodhouse L, McCormick A, Cross P, Edmondson R . Advanced Ovarian Cancer Displays Functional Intratumor Heterogeneity That Correlates to Ex Vivo Drug Sensitivity. Int J Gynecol Cancer. 2016; 26(6):1004-11. DOI: 10.1097/IGC.0000000000000745. View

14.

Weigelt B, Comino-Mendez I, de Bruijn I, Tian L, Meisel J, Garcia-Murillas I . Diverse and Reversion Mutations in Circulating Cell-Free DNA of Therapy-Resistant Breast or Ovarian Cancer. Clin Cancer Res. 2017; 23(21):6708-6720. PMC: 5728372. DOI: 10.1158/1078-0432.CCR-17-0544. View

15.

Lord C, Ashworth A . PARP inhibitors: Synthetic lethality in the clinic. Science. 2017; 355(6330):1152-1158. PMC: 6175050. DOI: 10.1126/science.aam7344. View

16.

Coleman R, Oza A, Lorusso D, Aghajanian C, Oaknin A, Dean A . Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017; 390(10106):1949-1961. PMC: 5901715. DOI: 10.1016/S0140-6736(17)32440-6. View

17.

Fujiwara K, Fujiwara H, Yoshida H, Satoh T, Yonemori K, Nagao S . Olaparib plus bevacizumab as maintenance therapy in patients with newly diagnosed, advanced ovarian cancer: Japan subset from the PAOLA-1/ENGOT-ov25 trial. J Gynecol Oncol. 2021; 32(5):e82. PMC: 8362816. DOI: 10.3802/jgo.2021.32.e82. View

18.

Timmermans M, Sonke G, Van de Vijver K, van der Aa M, Kruitwagen R . No improvement in long-term survival for epithelial ovarian cancer patients: A population-based study between 1989 and 2014 in the Netherlands. Eur J Cancer. 2017; 88:31-37. DOI: 10.1016/j.ejca.2017.10.030. View

19.

Mukhopadhyay A, Elattar A, Cerbinskaite A, Wilkinson S, Drew Y, Kyle S . Development of a functional assay for homologous recombination status in primary cultures of epithelial ovarian tumor and correlation with sensitivity to poly(ADP-ribose) polymerase inhibitors. Clin Cancer Res. 2010; 16(8):2344-51. DOI: 10.1158/1078-0432.CCR-09-2758. View

20.

Moore K, Secord A, Geller M, Miller D, Cloven N, Fleming G . Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial. Lancet Oncol. 2019; 20(5):636-648. DOI: 10.1016/S1470-2045(19)30029-4. View